| Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed (NCT07674368) | Hunan Cancer Hospital | 2026-07-10 |
| Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer (NCT07627620) | Hunan Cancer Hospital | 2026-06-30 |
| Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma (NCT07314216) | Hunan Cancer Hospital | 2026-06-22 |
| Precision Navigation to Improve Community Cancer Screening Participation (NCT07676383) | Hunan Cancer Hospital | 2026-06-01 |
| A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors (NCT07163481) | Hunan Cancer Hospital | 2025-10-01 |
| Lorlatinib in ROS1+ NSCLC With Brain Metastasis (NCT07083687) | Hunan Cancer Hospital | 2025-08-15 |
| Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer (NCT07098026) | Hunan Cancer Hospital | 2025-05-01 |
| Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer (NCT06840704) | Hunan Cancer Hospital | 2025-02-25 |
| LDRT and Chemoimmunotherapy in NPC With Liver Metastasis (NCT06788002) | Hunan Cancer Hospital | 2025-01-14 |
| Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) . (NCT06734533) | Hunan Cancer Hospital | 2024-12-05 |
| Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer (NCT06486545) | Hunan Cancer Hospital | 2024-08-25 |
| Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma (NCT06406634) | Hunan Cancer Hospital | 2024-05-15 |
| Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy (NCT06385990) | Hunan Cancer Hospital | 2024-03-29 |
| Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer (NCT06748495) | Hunan Cancer Hospital | 2024-02-05 |
| Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma (NCT06321939) | Hunan Cancer Hospital | 2024-01-11 |
| 18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors (NCT06557590) | Hunan Cancer Hospital | 2024-01-01 |
| Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer (NCT06543108) | Hunan Cancer Hospital | 2024-01-01 |
| Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer (NCT05842525) | Hunan Cancer Hospital | 2023-10-01 |
| A Real-world Study of Inetetamab for First-line Treatment of MBC (NCT05980208) | Hunan Cancer Hospital | 2023-09-01 |
| Clinical Study on Nutrition Intervention in Patients With Esophageal and Gastric Cancer Treated With Chemotherapy (NCT06022770) | Hunan Cancer Hospital | 2023-08-30 |
| A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC (NCT05940532) | Hunan Cancer Hospital | 2023-06-14 |
| Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer (NCT05633914) | Hunan Cancer Hospital | 2023-02-07 |
| Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC. (NCT06033287) | Hunan Cancer Hospital | 2023-01-01 |
| UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases (NCT05535413) | Hunan Cancer Hospital | 2023-01-01 |
| Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd (NCT07073755) | Hunan Cancer Hospital | 2023-01-01 |
| AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer (NCT05430906) | Hunan Cancer Hospital | 2022-11-25 |
| Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer (NCT05561686) | Hunan Cancer Hospital | 2022-10-01 |
| Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors (NCT05460481) | Hunan Cancer Hospital | 2022-06-12 |
| A Study of Carilizumab Combined With Concurrent Chemoradiotherapy (NCT05151549) | Hunan Cancer Hospital | 2021-12-01 |
| Research on Optimization and Evaluation of Oral Cancer Screening Methods (NCT04919460) | Hunan Cancer Hospital | 2021-06-01 |
| A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer (NCT04974827) | Hunan Cancer Hospital | 2021-05-20 |
| A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC) (NCT04767295) | Hunan Cancer Hospital | 2021-03-01 |
| A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs). (NCT04826406) | Hunan Cancer Hospital | 2021-02-03 |
| Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy (NCT05001971) | Hunan Cancer Hospital | 2021-01-30 |
| Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma (NCT04922450) | Hunan Cancer Hospital | 2021-01-20 |
| Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer (NCT05869097) | Hunan Cancer Hospital | 2020-11-01 |
| Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer (NCT05206656) | Hunan Cancer Hospital | 2020-10-09 |
| Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma (NCT04459078) | Hunan Cancer Hospital | 2020-08-26 |
| Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma (NCT04414969) | Hunan Cancer Hospital | 2020-06-26 |
| Real World Study on the Efficacy and Safety of Anti-HER2 Therapy (NCT05367739) | Hunan Cancer Hospital | 2020-06-01 |
| Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer (NCT04407988) | Hunan Cancer Hospital | 2019-11-06 |
| Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC (NCT03994744) | Hunan Cancer Hospital | 2019-08-20 |
| Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC (NCT06031376) | Hunan Cancer Hospital | 2019-07-01 |
| Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer (NCT05942768) | Hunan Cancer Hospital | 2019-07-01 |
| Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients (NCT05326295) | Hunan Cancer Hospital | 2019-03-01 |
| Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer (NCT04239443) | Hunan Cancer Hospital | 2019-01-30 |
| A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer (NCT03895788) | Hunan Cancer Hospital | 2019-01-14 |
| Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer (NCT03624309) | Hunan Cancer Hospital | 2018-10-15 |